Why the study?
Following variable behavioral benefit from myostatin inhibition in Acta1 mutant models, this study evaluated the effects of ActRIIB-mFc in a nebulin conditional knockout model of nemaline myopathy.
Does ActRIIB-mFc improve weight gain, strength, myofiber size, or hypertrophic pathway signaling in the Neb cKO mouse model of nemaline myopathy?
Does ActRIIB-mFc improve weight gain, strength, myofiber size, or hypertrophic pathway signaling in the Neb cKO mouse model of nemaline myopathy?
Answers are grounded in this paper and cite their sources.
Myostatin inhibition with ActRIIB-mFc does not provide therapeutic benefit in the nebulin conditional knockout mouse model of nemaline myopathy, contrasting with effects seen in other models.
Mutations in at least 12 genes are responsible for a group of congenital skeletal muscle diseases known as nemaline myopathies (NMs). NMs are associated with a range of clinical symptoms and pathological changes often including the presence of cytoplasmic rod-like structures (nemaline bodies) and myofiber hypotrophy. Our recent work has identified a variable degree of behavioral benefit when treating 2 NM mouse models due to mutations in Acta1 with myostatin inhibition. This study is focused on the effects of delivering ActRIIB-mFc (Acceleron; a myostatin inhibitor) to the nebulin conditional knockout KO (Neb cKO) mouse model of NM. Treatment of Neb cKO mice with ActRIIB-mFc did not produce increases in weight gain, strength, myofiber size, or hypertrophic pathway signaling. Overall, our studies demonstrate a lack of response in Neb cKO mice to myostatin inhibition, which differs from the response observed when treating other NM models.
No takes yet. Share an insight, caveat, or question.
Tinklenberg et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: